

James A Underberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5561730/james-a-underberg-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

1,188
citations

16
h-index

34
g-index

59
ext. papers

1,464
ext. citations

4.2
avg, IF

3.99
L-index

#	Paper	IF	Citations
48	A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.. <i>Journal of the American Heart Association</i> , 2022 , e024176	6	0
47	JCL Roundtable: Global Think Tank on Lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2021 , 15, 387-393	4.9	1
46	Characterization of PCSK9 in the Blood and Skin of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 308-315	4.3	8
45	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021 , 319, 51-61	3.1	12
44	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 398-413	4.9	29
43	Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). <i>Journal of Clinical Lipidology</i> , 2020 , 14, 807-817	4.9	14
42	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <i>Atherosclerosis</i> , 2019 , 289, 85-93	3.1	35
41	Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease. <i>Cardiology</i> , 2019 , 142, 83-90	1.6	8
40	Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. <i>American Heart Journal</i> , 2018 , 199, 37-43	4.9	4
39	LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). <i>Journal of the American College of Cardiology</i> , 2018 , 71, A168	15.1	4
38	Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 290-296	6.1	1
37	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 450-458.e1	4.9	21
36	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 880-890	4.9	73
35	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017 , 40, 243-254	3.3	52
34	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017 , 267, 19-26	3.1	36
33	The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 48	6	10
32	Genetic effects on efficacy of lipid-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1112-1117	4.9	2

31	Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics. <i>American Journal of Medicine</i> , 2017 , 130, 1233 ²⁻⁴		
30	Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1177-1180	4.9	9
29	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1300-1308		
28	Cardiovascular Effects of the New Weight Loss Agents. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 849-59	15.1	16
27	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. <i>Postgraduate Medicine</i> , 2016 , 128 Suppl 1, 31-9	3.7	4
26	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. <i>Annals of Internal Medicine</i> , 2016 , 165, 817-828	8	61
25	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 273-82	4.9	27
24	Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?. <i>Urologic Clinics of North America</i> , 2016 , 43, 247-60	2.9	5
23	JCL roundtable: Risk evaluation and mitigation strategy. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1288-1296	4.9	5
22	The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 494	6	7
21	Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 603-9	7.5	6
20	The National Lipid Association's new recommendations for patient-centered management of cholesterol. <i>Clinical Lipidology</i> , 2015 , 10, 13-15		
19	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015 , 9, S1-122.e1	4.9	293
18	Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <i>Contemporary Diabetes</i> , 2014 , 399-413	0	
17	Rationale and design of the familial hypercholesterolemia foundation CASCADE Screening for Awareness and DETection of Familial Hypercholesterolemia registry. <i>American Heart Journal</i> , 2014 , 167, 342-349.e17	4.9	63
16	Laparoscopic gastric banding resolves the metabolic syndrome and improves lipid profile over five years in obese patients with body mass index 30-40 kg/m ² . <i>Atherosclerosis</i> , 2014 , 237, 183-90	3.1	11
15	Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. <i>American Heart Journal</i> , 2014 , 168, 310-316.e3	4.9	8
14	Relationship between plasma apolipoprotein B concentrations and LDL particle number. <i>Research Reports in Clinical Cardiology</i> , 2014 , 237	0.1	

13	Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 390-6	3.1	26
12	Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 465-79	3.9	28
11	Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 573-609	4.9	16
10	2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease	15.1	81
9	New Treatment Approaches for Dyslipidemia and its Management. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 395-400	0.9	
8	2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data	16.7	111
7	2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease	1.3	14
6	The role of mipomersen therapy in the treatment of familial hypercholesterolemia. <i>Clinical Investigation</i> , 2012 , 2, 1033-1037		2
5	Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management. <i>Current Diabetes Reports</i> , 2011 , 11, 64-9	5.6	14
4	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing	16.7	21
3	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing	15.1	44
2	Utility of different lipid measures to predict coronary heart disease. <i>JAMA - Journal of the American Medical Association</i> ; 2008 , 299, 35-6; author reply 36 Utilization; America. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1336-63	27.4	
1	Bridging the gap in treatment options for patients with hypertriglyceridemia. <i>Journal of Family Practice</i> , 2007 , 56, S24-31	0.2	